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Abstract 
 
Previous research by the Mansky lab has demonstrated that BMP2 enhances 
RANKL-mediated osteoclast differentiation and activity.  To investigate the 
effects of other BMPs on osteoclast differentiation, I treated bone marrow 
macrophages with RANKL and increasing concentrations of BMP4, 6 or 7 during 
osteoclast differentiation.  Osteoclasts were TRAP stained and measured and 
counted using NIH Image J.  My results demonstrated that BMP4 and BMP6 
increased osteoclast size but not osteoclast number; however, BMP7 increased 
osteoclast number but not size.  Secondly I treated mature multinuclear 
osteoclasts with increasing concentrations of BMP 4, 6 and 7 to determine the 
effect of BMP on osteoclast activity.  An increase in osteoclast activity was only 
measured with the addition of BMP7 to mature osteoclasts.  My experiments 
demonstrate that similar to BMP2, BMP4, 6 and 7 enhance RANKL mediated 
osteoclast differentiation; however, the mechanism by which BMPs enhance 
differentiation still needs to be explored. 
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Introduction 
 
Bone is a vital component of one’s structural support and muscle 
attachment. As one of the few organs that continue to regenerate into adulthood, 
bone resorption and formation in normal circumstances occurs in cycles to 
maintain homeostasis (1). Maintenance of this homeostasis is vital for bone health 
and stability. When this balance is disturbed, whether due to trauma, autoimmune 
diseases, neoplasms, hormonal changes, or numerous other factors, it can result in 
a destructive manifestation that negatively impacts quality of life (2). This 
homeostasis occurs when the cells involved in building and breaking down bone 
complement each other and allow for bone remodeling. Bone remodeling is a 
lifelong process necessary to repair bone damage that involves bone cells, as well 
as proteins such as bone morphogenetic proteins (BMPs), and signaling pathways 
to achieve a balanced activity between bone resorption and apposition in order to 
maintain proper bone mass (3).  
Review of Literature 
 
Osteoblasts 
Osteoblasts are cells that originate from the mesenchymal lineage and are 
responsible for bone formation. When groups of these cells come together, they 
form an osteon and are then able to synthesize dense, crosslinked collagen and 
other specialized proteins (osteocalcin and osteopontin) that ultimately form bone. 
The coupling of bone resorption with bone formation in skeletal remodeling is 
primarily determined and regulated by osteoclast and osteoblast intracellular 
communication (4). The main purpose of the remodeling process is to resorb 
2 
 
away old bone by osteoclasts and subsequently lay down new bone by osteoblasts 
(4).  
Figure 1.  Bone remodeling cycle (5). 
Bone formation and resorption is a continuous, life long process with 5-
25% of bone surface undergoing bone remodeling at any given time. The four 
major stages are: activation, resorption, reversal, and formation (4). The 
remodeling cycle is initiated when quiescent bone surface covered with bone 
lining cells are activated and recruit osteoclast precursor cells (4). Once these 
cells fuse to the bone surface, they form into mature osteoclasts and begin 
resorbing bone. Resorption occurs by osteoclasts creating an acidic 
microenvironment and with the help of specific enzymes, degrading the organic 
bone matrix. During the reversal phase, preosteoblasts enter the newly resorbed 
cites and take residence in the resorption pits (4). Once there, these cells mature 
into osteoblasts and begin the bone formation process. During this process, some 
osteoblasts may become trapped in the mineralized matrix and become osteocytes 
(4). Osteocytes are the most common type of bone cell and responsible for 
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molecular synthesis and modification as well as signal transmission to maintain 
bone function.  
Osteoblasts are single nucleated cells of mesenchymal origin but work in 
groups of cells when activated to produce bone. They produce multiple 
specialized proteins including osteocalcin and osteopontin (1), which comprise 
the organic matrix of bone. Their main function is to fabricate and secrete an un-
mineralized protein matrix called osteoid (1). Once embedded in bone, they are 
called osteocytes. Osteoblasts and osteocytes communicate and regulate 
osteoclast differentiation (6). Such mediators include RANKL (Receptor activator 
of nuclear factor kappa-B ligand) and OPG (osteoprotegerin, also known as 
osteoclastogenesis inhibitory factor, (6).  
Osteoclastogenesis 
Osteoclasts are multinucleated cells that originate from hematopoietic 
stem cells (HSCs), which through a series of steps, commit to the 
monocyte/macrophage lineage and eventually mature to multinuclear osteoclasts 
(2). Histologically, the cytoplasm of osteoclasts is characterized by a foamy 
appearance due to a high concentration of vacuoles and vesicles containing acid 
phosphatase filled lysosomes. As mononuclear precursor cells, they begin to 
differentiate and fuse with other precursor cells to become multi-nucleated cells 
(7). Osteoclasts are responsible for bone resorption by degrading extracellular 
matrix and acidification of their environment (4).  The survival and activation of 
mature osteoclasts is dependent upon numerous hormones and cytokines. One 
important cytokine RANKL as discussed above has shown to increase the 
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osteoclast life cycle and permit cell function (2).  As a membrane-residing protein 
on osteoblasts and their precursors, RANKL activates RANK on osteoclast 
precursors stimulating osteoclast differentiation and activity through numerous 
pathways (8). M-CSF another essential factor for osteoclast differentiation is 
produced by stromal/osteoblasts cells and is required for osteoclast development 
and survival (9).  Together, RANKL and M-CSF are required for proper 
osteoclast differentiation (10).  
 
Figure 2. Differentiation of HSCs (haematopoietic stem cells) through osteoclast lineage 
via preosteoclasts, which fuse to form multinucleated cells, before maturing into 
osteoclasts. This process requires both M-CSF (macrophage-colony stimulating factor) 
and RANKL (receptor activator nuclear factor kappa B ligand). OPG (osteoprogerin) is 
required for inhibition. Expression of TRAP (tartrate resistant acid phosphate) and CT 
(calcitonin) receptors are induced with RANKL stimulation.  
 
RANKL regulatory pathway 
As a member of the TNF (tumor necrosis factor) superfamily, RANKL has 
traditionally thought to be expressed primarily by bone marrow stromal cells and 
osteoblasts to stimulate osteoclast differentiation upon binding to the RANK 
receptor on osteoclast precursor cells (8). Yet, recent research has shown the 
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important role osteocytes play in the production and secretion of RANKL (11, 12) 
Both in vivo and in vitro, the loss of RANKL results in the absence of 
osteoclastogenesis and an osteopetrotic phenotype (11, 12). Based on mouse 
models, osteoblasts are hypothesized to regulate osteoclast differentiation in 
developing animals while osteocytes regulate osteoclast differentiation in mature 
animals (11).  A decoy receptor that sequestrates RANKL from binding RANK 
when activation is undesired is osteoprotegrin (OPG) (13). If OPG is overly 
expressed, this too can lead to RANKL inactivation and lack of osteoclastogenesis 
(13). Systemic hormones such as parathyroid hormone, vitamin D3, calcitonin, as 
well as other local autocrine and paracrine factors (TNF-α, IL-1, etc.) can regulate 
osteoclastogenesis (14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
Figure 3. RANKL is expressed on the surface of osteoblast and stromal cells that 
release OPG into the extracellular matrix. RANKL binds RANK on the surface of 
osteoclast precursors and stimulates osteoclast differentiation and activation once 
cell to cell contact is achieved. OPG acts as a decoy receptor to prevent binding of 
RANKL to RANK. 
 
Osteoclast Role in Dentistry and Orthodontics 
The role of osteoclasts is paramount in the field of dentistry. Although the 
remodeling process of bone is constant and ongoing in the maxilla, mandible, and 
alveolar processes, there are several instances where osteoclast function is 
required in order to achieve a desired outcome set by the practitioner and/or 
maintain homeostasis (15).  
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Figure 4. Orthodontic Force resulting in bone remodeling (16). 
Such circumstances included the extraction of teeth, whether to discard an 
unrestorable tooth, or create space for comprehensive orthodontic treatment where 
the patient presents with severe crowding. In such cases, the tooth socket (bone) is 
exposed to the oral cavity and only separated by a thin biofilm. Over time, this 
portion of exposed bone houses resorption lacuna where osteoclasts separate the 
dead bone from the underlying healthy bone (M). This process allows for the 
removal of necrotic bone and initiation of new bone mineralization in the socket 
site. Osteoclasts also play a key role in orthodontic tooth movement.  
 
Bone Morphogenetic Proteins (BMPs):  
BMPs are members of the TGF-β superfamily of polypeptides and regulate cell 
differentiation, proliferation, and apoptosis at the cellular level in osteoblasts, 
osteoclasts, and chondrocytes in both embryonic and postnatal stages (3). They 
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were first discovered forty years ago by Urist as an osteoinductive component of 
demineralized bone matrix (17). The BMP family also plays a role in 
organogenesis of the heart, gut, lung, teeth, kidney, and skin as well as cartilage 
and bone (18). Within the TGF-β superfamily of growth factors, BMPs are the 
largest group and distinguished from other members in the group by containing 
two extra conserved cysteine amino acids as opposed to the standard seven that 
are folded into a cysteine knot (18). BMPs’ general role in the pathophysiology of 
fracture healing and skeletal development has been broadly explored (19). BMPs 
critical presence in osteoclast and osteoblast development implies they also play a 
key role in bone remodeling (3, 19).  
 
BMP regulation and signaling pathway:  
 
There are several antagonists (both intracellular and extracellular) that regulate 
BMP activity. Intracellular antagonists that regulate BMP signaling include 
Smad6, Smad7, Smad8d, Smurf1, and Smurf2 (18) while extracellular antagonists 
include noggin, chordin, twisted gastrulation, gremlin, and follistatin (18).  There 
are multiple ligands and receptors involved in the BMP signaling pathway. It is 
important to note that BMPs can behave in both a paracrine and autocrine model 
(18); however, the mechanism by which they regulate osteoclast differentiation 
and activity is unknown. The signaling initiation begins when BMPs bind to two 
surface receptors - Type 1R/BMPRII and Type IR/ALK2, 3, 6. These receptors 
activate the SMAD or canonical pathway or MAPKs (mitogen-activated protein 
kinase) or noncanonical signaling transduction pathways (3, 20).  
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Figure 5. Extracellular and intracellular inhibitors modulate BMP’s signaling pathway 
once BMP binds to a surface BMP receptor I and II. This downstream signaling pathway 
includes the canonical Smad and non-canonical Smad independent pathways and 
eventually results in regulating osteoblast and osteoclast differentiation and activation 
genes.  
 
 
BMP and Osteoclast differentiation:  
 
BMP2 does not only affect osteoblast differentiation and activity, but as the 
Mansky/Gopalakrishan lab and others have shown that BMP2 increases osteoclast 
differentiation and function (21-25). Both early lineage cells (bone marrow 
macrophages) and mature osteoclasts express BMP2 (25, 26).  In early 
hematopoetic stem cells, BMP2 can increase or decrease cell proliferation, 
depending on concentration, but BMP stimulation does not affect lineage 
commitment (27).  In lineage committed OCLs, BMP2 acts to enhance survival 
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and proliferation, and its phenotypic effect can be potentiated by IL-1A, 
prostaglandin, vitamin D3, and PTH (26, 28, 29).  Both BMP2 and 4 are highly 
expressed by osteoclasts at fracture sites (30).  Overexpression of BMP4 in bone 
leads to osteopenia due to increased osteoclast number (31).  Due to its ability to 
induce bone formation, although less potently than BMP 2/6/9, BMP7 has been 
approved by the FDA for use in lumbar fusions.  BMP7 like BMP2 and BMP4 
results in enhanced resorption at fracture site (32). 
 
BMPs and their clinical use 
BMPs have also shown to increase the rate of healing and reduced secondary 
intervention in anterior lumbar interbody spine fusions, open tibia fractures, 
reoperation of failed posterolateral spine fusions, and recalcitrant nonunions in 
preclinical studies (33).  In 2004, the FDA approved BMP-2, marketed as Infuse 
(Medtronic Sofamor Danek) for treating open tibial shaft fractures. Additionally, 
BMP-2, when delivered as an absorbable collagen sponge, can treat metaphyseal 
core defects resulting in bone resorption followed by bone formation in 
nonhuman primates (33).  In one clinical study using rh-BMP2 in transforaminal 
lumbar interbody fusion almost all subjects contained active resorption (92%), 
and 69% of patients showed lumbar level defects (34). As related to the dental 
profession, BMP-7, when placed directly in a Class III periodontal defect 
furcation in dogs, showed marked stimulation of regenerative cementum, 
osteogenesis and increased attachment formation (35). Research conducted with 
isolated mice molars pretreated with BMP-2 and BMP-4 notably displayed 
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accelerated alveolar bone development (36).  Although the existing published 
research regarding BMP’s has the potential to have significant clinical 
implications, there is still a necessity to learn more about these potent proteins.  
 
Hypotheses:  
Because there is much unknown about how specific BMPs directly regulate 
osteoclast differentiation, this research will address the following hypothesis:  
1. Treating osteoclasts with RANKL+ increasing concentrations of BMP 4, 
6, or 7 during osteoclast differentiation will enhance differentiation 
compared to RANKL only treated osteoclasts. 
2. Treating mature multinuclear osteoclasts with RANKL+ increasing 
concentrations of BMP 4, 6 or 7 will result in increased osteoclast activity 
(resorption) compared to RANKL only treated osteoclasts.  
If my hypotheses are correct, I expect to see an increase in the size of the 
osteoclasts treated with BMP4, 6 and/or 7 compared to RANKL only treated 
osteoclasts.  We may not see an increase in osteoclast number since in the 
Mansky’s lab experience as the size of the osteoclasts increase due to increase 
fusion then the number of osteoclasts actually decreases. Lastly we expect that 
mature (i.e. multinuclear) osteoclasts when treated with either BMP 4, 6 and/or 7 
will have more activity than osteoclasts treated with RANKL only. If confirmed, 
implications to this outcome would be important for understanding the 
mechanisms by which different BMPs regulate osteoclast differentiation and for 
the clinical applications associated with the use of BMPs.   
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Materials and Methods:  
 
Figure 6. Methods A. Population being studied wild type mice, mice femur 
dissected, bone marrow cells harvested. B. Cells counted using counting 
chambers. C. Cells plated in each well for either differentiation (coated plastic) or 
resorption (calcium/phosphate coated). D. Resorption and differentiation wells fed 
with RANKL and MCSF along with varying degrees of BMP concentration.  
 
Harvesting of bone marrow/Primary OCLs 
Primary bone marrow macrophages were harvested from the femurs and tibiae of 
4-week-old C57Bl6 mice.  The femurs and tibiae were dissected and adherent 
tissue was removed.  The ends of the bones were cut and the marrow was flushed 
from the inner compartments.  Red blood cells (RBC) were lysed from the flushed 
bone marrow tissue with RBC lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 
mM EDTA, pH7.4) and the remaining cells were plated on 100 mm plates and 
cultured overnight in osteoclast medium (phenol red-free Alpha-MEM (Gibco) 
with 5% heat-inactivated fetal bovine serum (Hyclone), 25 units/mL 
penicillin/streptomycin (Invitrogen), 400 mM L-Glutamine (Invitrogen), and 
supplemented with 1% CMG 14-12 culture supernatant containing M-CSF).  The 
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non-adherent cell population, including osteoclast precursor cells, was then 
carefully separated and re-plated at approximately 200,000 cells/well in a 12 well 
plate with osteoclast medium supplemented with 1% CMG 14-12 culture 
supernatant.   Two days later, this medium was replaced with medium containing 
1% CMG 14-12 culture supernatant and 20 ng/mL RANKL (R&D Systems) to 
stimulate osteoclast differentiation. For osteoclast resorption assays, experiments 
were performed and quantitated using calcium phosphate plates (Corning).  
TRAP Stain 
Primary osteoclasts were fixed with 4% paraformaldehyde (PFA) and washed 
with PBS.  The cells were then stained for tartrate resistant acid phosphatase 
(TRAP) expression with tartrate 5 mg, Naphthol AS-MX phosphate, 0.5 mL M, 
M-Dimethyl formamide, 50 mL acetic acid buffer (1 mL acetic acid, 6.8 g sodium 
acetate trihydrate, 11.5 g sodium tartrate in 1 L water) and 25 mg Fast Violet LB 
salt. Cells were then observed and captured with light microscopy and the 
measurements were analyzed using NIH Image J.   
Resorption Assays 
Primary osteoclasts were plated on Corning Osteo Assay Surface plates at a 
density of 100,000 cells per well.  Cells were allowed to fully differentiate with 
RANKL until multinuclear cells appeared.  Differentiation medium was 
supplemented with 200 ng/ml BMP2 or indicated doses of BMP 4, 6 or 7 (50-200 
ng/ml, R&D Systems) for 24 hours.  For all the resorption assays, the media was 
completely removed 24 hours after the addition of BMPs and 100μL/ well of 10% 
bleach was added and allowed to incubate at room temperature for 5 minutes.  
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The bleach solution was then aspirated and the wells were washed twice with 
150μL of dH2O.  The plate was then allowed to air dry completely at room 
temperature for 3-5 hours.  The wells were observed at 4x magnification for the 
formation of resorption pits and images were captured with light microscopy.  
Images were measured and analyzed using NIH Image J.  For Image J analysis, 
images were converted to binary (black and white) and parameters in Image J 
were set so that only osteoclasts that were multinuclear (greater than 3 nuclei) 
were counted and measured.   
Statistics 
All experiments were completed in triplicate and performed at least three times.  
The data shown are representative of the mean + SD of all experiments.  One way 
ANOVA analysis followed by a Tukey’s multiple comparison test were used to 
compare data; p<0.05 indicates significance.  Statistical analysis was performed 
using Prism 5 software for Mac OSX. 
 
Results 
Previous results from the Mansky/Gopalakrishnan lab have demonstrated 
that BMP2 enhances osteoclast differentiation through enhancement of osteoclast 
fusion (21-23, 25, 37).  A limitation to the Mansky/Gopalakrishnan’s previous 
studies is that they only tested BMP2’s effect on osteoclast differentiation and no 
other BMP ligands.  Preliminary studies from the Mansky/Gopalakrishan lab have 
shown that osteoclasts express RNA for BMP ligands 4 and 6 as well as BMP2 
(Mansky, personal communication).  In order to determine how other BMP 
ligands affect osteoclasts, bone marrow cells were isolated from wild-type mice 
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and osteoclasts were cultured.  To measure the effect of BMP 4, 6 or 7 on 
osteoclast differentiation osteoclasts were treated with three different 
concentrations of each BMP ligand (50, 100, 200 ng/mL) and compared to 
RANK-L alone. BMP2 + RANK-L was used as a positive control. The cells were 
then photographed and NIH Image J was used to determine the size or number of 
cells. Each BMP ligand was compared to the control and at each different 
concentration level.  
Figure 7. BMP6 enhances osteoclast differentiation. BMMs were differentiated 
in the presence of M-CSF and RANKL, BMP2 (200 ng/mL) or various 
concentrations of BMP6.  Osteoclasts were TRAP stained, imaged and quantified.  
Only cells with 3 or more nuclei were quantified. (A) Representative image of 
TRAP stained cells (B) osteoclast number and (C) osteoclast size.  
To analyze osteoclast number and size, each well was photographed using 
a microscope equipped with a digital camera. The captured image was analyzed 
by the NIH Image J software. Triplicate photographs were taken from each well at 
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4x magnification. Area measures were completed for both control and cells 
treated with the varying BMP ligands. As shown in Figure 7-9 and as previously 
reported, osteoclasts treated with BMP2 compared to RANKL only treated cells 
showed an increase in osteoclast size (Figure 7-9C, p<0.05) but no significant 
change in osteoclast number (Figure 7-9B).   
To examine the effect of BMP6 on osteoclast differentiation, osteoclast 
precursors were platted in the presence of RANKL and varying (increasing) doses 
of the BMP6. Osteoclasts were TRAP stained, imaged, and analyzed using NIH 
Image J software to assess osteoclast size and number. As you can see in Figure 
7B, BMP6 at the lower dose of 50 ng/mL increased the number of TRAP+ 
multinuclear cells, while at higher doses (100 and 200 ng/mL), BMP6 increased 
the size of the osteoclasts similar to that measured with BMP2 (Figure 7C). 
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Figure 8. BMP4 Enhances Osteoclast Differentiation. BMMs were 
differentiated in the presence of M-CSF and RANKL, BMP2 (200 ng/mL) or 
various concentrations of BMP4. Osteoclasts were TRAP stained, imaged and 
quantified.  Only cells with 3 or more nuclei were quantified. (A) Representative 
image of TRAP stained cells (B) osteoclast number and (C) osteoclast size. 
  
To examine the effect of BMP4 on osteoclast differentiation, osteoclast 
precursors were plated in the presence of RANKL and varying (50, 100 or 200 
ng/mL) concentrations of the BMP4. Osteoclasts were TRAP stained, imaged, 
and analyzed using NIH Image J software to measure osteoclast size and number. 
As you can see in Figure 8, BMP4 at the lower dose of 50 and 100 ng/mL 
increased the size of TRAP+ multinuclear cells compared to RANKL only treated 
cells (Figure 8C), while there was no statistically difference in osteoclast number 
when comparing osteoclasts treated with RANKL alone and osteoclasts treated 
with RANKL and BMP4. 
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Figure 9.  BMP7 Enhances Osteoclast Number.  BMMs were differentiated in 
the presence of M-CSF and RANKL, BMP2 (200 ng/mL) or various 
concentrations of BMP4.  Osteoclasts were TRAP stained, imaged and quantified.  
Only cells with 3 or more nuclei were quantified.  (A) Representative image of 
TRAP stained cells (B) osteoclast number and (C) osteoclast size.  
To examine the effect of BMP7 on osteoclast differentiation, osteoclast 
precursors were platted in the presence of RANKL and varying (50, 100 and 200 
ng/mL) concentrations of the BMP7. Osteoclasts were TRAP stained, imaged, 
and analyzed using NIH Image J software to assess osteoclast size and number. 
As you can see in Figure 9, there is an increase in the number of osteoclasts in the 
presence of BMP7 and RANKL (Figure 9B) when compared with RANKL alone 
but no significant effect on osteoclast size in the presence of BMP7 compared to 
RANKL alone (Figure 9C).  
In the second part of my study, I wanted to separate the effects of BMPs on 
osteoclast differentiation and activity by determining if BMP 4, 6 and 7 enhanced 
osteoclast activity on mature osteoclasts. For this part of the study, BMMs (bone 
marrow macrophages) were differentiated on calcium/phosphate coated plates 
into osteoclasts in the presence of M-CSF and RANKL until multinuclear cells 
appeared.  Once multinuclear or mature cells appeared, BMP 4, 6 or 7 were added 
at various concentrations for 24 hours.  Plates were treated to remove cells, 
imaged and quantified using NIH Image J.    
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Figure 10. BMP 6 Effects on Osteoclast Resorption.  BMMs were flushed from 
mice and plated on calcium phosphate coated plates in the presence of M-CSF 
and RANKL.  (A-D) Various concentrations of BMP6 were added to multinuclear 
osteoclasts for 24 hours.  (A) Representative images of calcium phosphate coated 
wells.  Quantification of  (B) percent area resorbed, (C) average size of pits, (D) 
number of pits. 
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Figure 11. BMP4 Effects on Osteoclast Resorption.  BMMs were flushed from 
mice and plated on calcium phosphate coated plates in the presence of M-CSF 
and RANKL.  (A-D) Various concentrations of BMP4 were added to multinuclear 
osteoclasts for 24 hours.   (A) Representative images of calcium phosphate coated 
wells. Quantification of  (B) percent area resorbed, (C) average size of pits, (D) 
number of pits. 
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Figure 12. BMP7 Effects on Osteoclast Resorption.  BMMs were flushed from 
mice and plated on calcium phosphate coated plates in the presence of M-CSF 
and RANKL.  (A-D) Various concentrations of BMP7 were added to multinuclear 
osteoclasts for 24 hours.   (A) Representative images of calcium phosphate coated 
wells.  Quantification of  (B) percent area resorbed, (C) average size of pits, (D) 
number of pits. 
 As is shown in Figures 10 and 11, there is no statistically significant 
difference between BMP6 (Figure 10B-C) or BMP4 (Figure 11B-C) treated 
osteoclasts compared to RANKL only treated when measuring osteoclast activity.  
However in Figure 12 treatment of mature osteoclasts with BMP7 significantly 
enhances osteoclast activity compared to RANKL treated osteoclasts. There is an 
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approximate two-fold increase in percent resorbed as the BMP7 concentration 
level increases as well as an increase at 200 ng/mL in pit size.  It appears as the 
areas of resorption increased in size, the pit number decreased which could be due 
to the coalescing of the pits as seen in Figure 12A RANKL + BMP7 (200).  
Discussion: 
Previously the Mansky/Gopalakrishnan lab had published that addition of 
exogenously added BMP2 to osteoclast cultures enhanced RANKL activation of 
osteoclast differentiation (25).  To further support the direct role of BMPs to 
regulate osteoclasts, the Mansky/Gopalakrishnan went on to further demonstrate 
that loss of BMP receptor type II in osteoclasts leads to a decrease in osteoclast 
differentiation and an osteopetrotic phenotype in null mice (22).  Previous 
research from other labs had shown the role of BMPs in regulating osteoclasts 
through regulation of osteoclast precursors (M-CSF), differentiation factors 
(RANK-L), and inhibitory factors (OPG).  Up to this point the studies from the 
Mansky/Gopalakrishnan lab have focused on the effect of BMP2 on osteoclast 
differentiation and activity.  My research project focused on the effect of BMP 4, 
6 and 7 on osteoclast differentiation and activity.  I chose to experimentally test 
BMP 4, 6 and 7 because besides BMP 2, BMP 4, 6 and 7 are the most highly 
expressed BMPs in the bone. I experimentally tested whether addition of BMP 4, 
6 or 7 to RANKL treated osteoclasts would enhance osteoclast differentiation.    
Based on my results, I determined that BMP 4 and BMP 6 enhanced the size of 
TRAP positive osteoclasts (Figure 7-8) but not osteoclast number.  However, 
when I tested the addition of BMP7 to osteoclast cultures, I found that BMP7 
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increased number of TRAP positive osteoclasts but not osteoclast size (Figure 9).  
This data suggests that BMP7 may act to enhance osteoclast differentiation 
through a different mechanism compared to BMPs 2, 4 and 6.  
I also determined whether there is an increase in osteoclast activity when 
BMP 4, 6 or 7 where added to mature osteoclasts. As shown in figures 10-12, I 
only measured an increase in osteoclast activity compared to RANKL treated 
osteoclasts with the addition of BMP 7 (see Figure 12).  One caveat to the 
experiments looking at the effects of BMPs on osteoclast activity is that I did not 
measure an increase in activity of mature osteoclasts with the addition of BMP2 
as previously published by the Mansky/Gopalakrishnan lab (23).   It is not clear at 
this time why I was not able to measure an increase in activity with BMP2 but the 
Mansky lab is in the process of repeating those experiments under different 
conditions.   
   The goal of these experiments was to gain a better understanding of 
BMP’s and their influence on osteoclasts. BMP’s have been shown to be effective 
in treating healing fractures, bone defects in long bones and the cranium and even 
alveolar bone regeneration in animal studies (20). The FDA has only approved 
limited use of recombinant BMPs clinically since the full scope of BMP’s effect 
on other cells is not fully understood. Long bone nonunion fractures, lumbar 
spinal fusion, and alveolar ridge/sinus augmentation are the few applications 
rhBMP are currently approved for in the clinic.  It is important to note that in the 
case of lumbar spinal fusion application, conflicting reports have been published 
where the outcome was undesirable such as ectopic bone formation (32).  Besides 
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bone metabolic disorders, gained knowledge about BMPs can influence the way 
we practice orthodontics. Influencing bone resorption and deposition may be used 
in various ways such as increasing tooth movement rates and increase bone 
healing/integration rates after bone grafting (especially for our cleft lip/palate 
patients). Ultimately, the use of BMPs has the potential to reduce treatment time 
for our orthodontic patients and increase the success rates of certain procedures 
that involve bone remodeling and regeneration.  
Conclusion 
There is lack of understanding about the pathway from osteoclast 
precursor cells committing to the lineage and fusion between differentiated 
osteoclasts. BMP6 and BMP4 were able to enhance osteoclast size during 
differentiation with BMP4 more active at lower doses when compared to BMP6. 
BMP7 appears to enhance osteoclast in number rather than size and this may 
suggest a different mechanism of action when compared to BMP4 and BMP6. 
BMP 4 and 6 do not appear to affect osteoclast resorption. BMP7 appears to 
increase resorption at higher doses when compared to RANKL. Experiments 
exploring mechanisms to understand how BMPs increase osteoclast size, number 
and activity are currently ongoing in the Mansky/Gopalakrishnan lab.   
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